Dividend
-
-
-
-
-
-
-
Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
-
-
-
-
-
-
-
Amgen (AMGN), UCB Announce FDA Advisory Committee Meeting To Review EVENITY
-
-
-
-
-
-
-
Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
-
-
-
-
-
-
-
Amgen (AMGN), UCB Announce FDA Acceptance of BLA For Romosozumab
-
-
-
-
-
-
-
Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
-
-
-
-
-
-
436,668 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

